Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30033828HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033829HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033830HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033831HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033832HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033833HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033834HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS30033835HIVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS20040094HPVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TVIS20040611HPVENSG00000059758.8protein_codingCDK17NoNo5128Q00537
TCGA Plot Options
Drug Information
GeneCDK17
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009511
UniProt IDQ00537
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830